Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
QXO heads into the week with shorts at a nine-month high, a freshly slashed analyst target, and a stock still trading at less than half the Street's consensus price.
The most striking development this week came from RBC Capital, where analyst Mike Dahl trimmed his price target on QXO by a third, from $27 to $18, while keeping his Outperform rating. That move, filed today, crystallises a pattern that has been building since the spring: analysts remain structurally bullish on the QXO roll-up story but are marking their targets lower as execution timelines stretch. The consensus mean target of $28.94 represents more than double the current price of $12.11, yet that gap has been closing from the wrong direction. Morgan Stanley reinstated coverage in August with a $35 Overweight. DA Davidson initiated at Buy with a $26 target. Citi and Keybanc have both trimmed targets across multiple rounds. Every firm that has touched the stock in 2026 has kept a positive rating, but the target cuts outnumber the raises by a wide margin. The bull case rests on a fragmented $800 billion North American building products market, the pending TopBuild acquisition, and pro forma 2030 revenue targets of $35 billion. The bear case is simpler: the plan works only if acquisitions keep coming at the right price, integration holds, and the rate environment cooperates.
Short positioning reinforces the skepticism. Short interest has climbed to 19.6% of free float, up 6.5% on the week and up nearly 59% over the past month. That monthly move is the standout: in late August, around 82 to 84 million shares were short; the count has now crossed 131 million. That is a substantial build in a stock where the bull thesis is explicitly long-term and dependent on deal flow. The ORTEX short score sits at 72.9, which places QXO in the bottom few percent of the universe on this metric, ranking 3rd percentile on short score and 8th on days-to-cover. Days to cover from the most recent FINRA fortnightly print runs at 7 days, meaning shorts would need more than a week of average volume to fully unwind. Despite all of this, the borrow market is not tight. Availability is currently at 72%, which means there are roughly 417 million shares still available to lend against 131 million already borrowed. Cost to borrow is only 0.76%, elevated slightly from a month ago but still near the bottom of any meaningful range. The lending pool remains deep. Shorts are building, but they are not yet being squeezed.
Options positioning leans call-heavy, which is the one angle that pushes back against the bearish read. The put/call ratio is 0.29, near its 52-week low of 0.24 and running about 1.3 standard deviations above its 20-day average, but still firmly in bullish-skew territory by any absolute measure. The 52-week high on the PCR is 0.83, so even at the current slightly elevated reading, options traders are running more calls than puts by a wide margin. That could reflect speculative positioning on a turnaround or deal catalyst, or it could reflect hedging against a short book. Either way, options are not corroborating the short sellers.
Among larger shareholders, the activist register is one of the more unusual features of this stock. Bradley Jacobs, the founder and driver of the QXO thesis, holds a 13D position representing 35.9% of the company, down from 49.0% as last disclosed in April 2026. Jared Kushner filed a 13D/A in August 2025 showing a stake of 4.9%, trimmed from 6.3%. Orbis Investment Management holds 10.2% on a 13G filing, steady as of August 2026. Baillie Gifford and BlackRock both crossed the 5% disclosure threshold for the first time in filings from August and July respectively. Invesco has trimmed its stake to around 5.0% from 6.7%. These moves as last disclosed, and holders can fall below the 5% threshold without a further filing, so actual positions may have shifted since. On the institutional side, the largest recent mover is Baillie Gifford, which added 34 million shares to reach 47.9 million as of June 30.
Earnings arrive on November 13. The prior three prints have each seen the stock fall on the day, with moves of 1.2%, 3.5%, and 4.2% respectively. The five-day window after the August print saw a further 11.2% decline. With short interest near its highest level since QXO began its transformation and a freshly reduced analyst target now barely above the current price, the November print becomes less about whether the roll-up strategy is working and more about whether the pace of deal integration and the TopBuild timeline can arrest the pattern of downward target revisions.
See the live data behind this article on ORTEX.
Open QXO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
